Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Institutional open access agreements
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Institutional open access agreements
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions

Randomised controlled trial of cognitive behavioural therapy in COPD

Karen Heslop-Marshall, Christine Baker, Debbie Carrick-Sen, Julia Newton, Carlos Echevarria, Chris Stenton, Michelle Jambon, Joanne Gray, Kim Pearce, Graham Burns, Anthony De Soyza
ERJ Open Research 2018 4: 00094-2018; DOI: 10.1183/23120541.00094-2018
Karen Heslop-Marshall
1Chest Clinic, Newcastle upon Tyne Hospitals NHS Foundation Trust, RVI Hospital, Newcastle upon Tyne, UK
2Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle upon Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: karen.marshall1@ncl.ac.uk
Christine Baker
3Dept of Clinical Health Psychology, Newcastle upon Tyne Hospitals NHS Foundation Trust, RVI Hospital, Newcastle upon Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Debbie Carrick-Sen
4Nursing Dept, School of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
5Heart of England NHS Trust, Birmingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Newton
2Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle upon Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos Echevarria
1Chest Clinic, Newcastle upon Tyne Hospitals NHS Foundation Trust, RVI Hospital, Newcastle upon Tyne, UK
2Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle upon Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chris Stenton
1Chest Clinic, Newcastle upon Tyne Hospitals NHS Foundation Trust, RVI Hospital, Newcastle upon Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle Jambon
6Community Chest Team, Newcastle Upon Tyne Hospitals NHS Foundation Trust, RVI Hospital, Newcastle upon Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joanne Gray
7Faculty of Health and Life Science, Northumbria University, Newcastle upon Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kim Pearce
2Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle upon Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Graham Burns
1Chest Clinic, Newcastle upon Tyne Hospitals NHS Foundation Trust, RVI Hospital, Newcastle upon Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony De Soyza
2Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle upon Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anthony De Soyza
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Anxiety is an important comorbidity in chronic obstructive pulmonary disease (COPD). We investigated if cognitive behavioural therapy (CBT), delivered by respiratory nurses, reduced symptoms of anxiety and was cost-effective.

Patients with COPD and anxiety were randomised to CBT or self-help leaflets. Anxiety, depression and quality of life were measured at baseline, 3, 6 and 12 months. A cost-effectiveness analysis was conducted from a National Health Service hospital perspective and quality-adjusted life-years estimated using the EuroQol-5D questionnaire.

In total, 279 patients were recruited. Group mean change from baseline to 3 months in the Hospital Anxiety and Depression Anxiety Subscale was 3.4 (95% CI 2.62–4.17, p<0.001) for the CBT group and 1.88 (95% CI 1.19–2.55, p<0.001) in the leaflet group. The CBT group was superior to leaflets at 3 months (mean difference in the Hospital Anxiety and Depression Anxiety Subscale was 1.52, 95% CI 0.49–2.54, p=0.003). Importantly, the CBT intervention was more cost-effective than leaflets at 12 months, significantly lowering hospital admissions and attendance at emergency departments.

CBT delivered by respiratory nurses is a clinically and cost-effective treatment for anxiety in patients with COPD relative to self-help leaflets.

Abstract

Cognitive behavioural therapy (CBT) delivered by respiratory nurses is clinically effective and cost-effective for patients with chronic obstructive pulmonary disease and symptoms of anxiety http://ow.ly/o41o30msBNy

Footnotes

  • This article has supplementary material available from openres.ersjournals.com

  • This study is registered at www.isrctn.com with identifier number ISCRTN 55206395. The authors are happy to share the study protocol, statistical analysis plan, informed consent form, patient information leaflet, data collection form and anonymised data with researchers who provide a methodologically sound proposal. The data will be available for 5 years after the article is published.

  • Conflict of interest: D. Carrick-Sen has nothing to disclose.

  • Conflict of interest: C. Baker reports grants from National Institute for Health Research (NIHR)/Health Education England (support for part-time PhD fellowship for K. Heslop-Marshall), non-financial support from University of Newcastle upon Tyne (advice for Nick Steen, Medical Statistician, Newcastle University), during the conduct of the study.

  • Conflict of interest: J. Gray has nothing to disclose.

  • Conflict of interest: J. Newton has nothing to disclose.

  • Conflict of interest: C. Stenton has nothing to disclose.

  • Conflict of interest: M. Jambon has nothing to disclose.

  • Conflict of interest: K. Pearce has nothing to disclose.

  • Conflict of interest: K. Heslop-Marshall reports grants from National Institute for Health Research (UK), during the conduct of the study; and other from Pivotal Health Education Ltd, outside the submitted work. (This research was completed in February 2016. In 2017, K. Heslop-Marshall set up a company to provide cognitive behavioural therapy (CBT) training for healthcare professionals who would like to learn foundation level skills in CBT to work with patients with long-term conditions who have psychological distress. This training will not just benefit professionals working in the respiratory setting. I did this to enhance the psychological skills and pass on my knowledge and expertise in CBT. This did not influence the research submitted in any way.)

  • Conflict of interest: G. Burns reports personal fees from BI, Chiesi and AZ (for advice on inhalers, not directly relevant to this study), personal fees from Teva (for three educational (non-promotional) talks on COPD, not related to this study), personal fees from Chiesi (for three educational (non-promotional) talks on COPD, not related to this study), personal fees from Pfizer and AZ (for educational (non-promotional) talks on COPD, not related to this study), all outside the submitted work.

  • Conflict of interest: A. De Soyza reports other from AstraZeneca (bronchiectasis interest group meeting support), non-financial support from Novartis (in kind support for analysis in bronchiectasis), non-financial support from Forest labs (bronchiectasis interest group meeting support), personal fees from Bayer (speakers’/advisory boards on bronchiectasis), personal fees and other from Novartis (advisory boards on bronchiectasis and in kind bench science support), other from Chiesi (travel bursary to attend ERS meeting), other from Almirall (travel bursary to attend ERS meeting), other from Boehringer Ingelheim (travel bursary to attend BTS meeting), personal fees from AstraZeneca (speakers’/advisory boards on COPD), grants from AstraZeneca (travel bursary to attend ATS meeting), all outside the submitted work. In addition, A. De Soyza has received medical education grant support for a UK bronchiectasis network from GSK, Gilead, Chiesi and Forest labs. A. De Soyza's employing institution receives fees for his work as Coordinating investigator in a phase III trial in Bronchiectasis sponsored by Bayer.

  • Conflict of interest: C. Echevarria has nothing to disclose.

  • Support statement: This study was supported by the Department of Health, National Institute for Health Research, Research Trainees Coordinating Centre 10-023. This article presents independent research funded as part of a part-time PhD fellowship to K. Heslop-Marshall funded by the National Institute for Health Research (NIHR) and includes work funded by Health Education England. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received June 17, 2018.
  • Accepted October 12, 2018.
  • Copyright ©ERS 2018

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

View Full Text
PreviousNext
Back to top
Vol 4 Issue 4 Table of Contents
ERJ Open Research: 4 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Randomised controlled trial of cognitive behavioural therapy in COPD
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Randomised controlled trial of cognitive behavioural therapy in COPD
Karen Heslop-Marshall, Christine Baker, Debbie Carrick-Sen, Julia Newton, Carlos Echevarria, Chris Stenton, Michelle Jambon, Joanne Gray, Kim Pearce, Graham Burns, Anthony De Soyza
ERJ Open Research Oct 2018, 4 (4) 00094-2018; DOI: 10.1183/23120541.00094-2018

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Randomised controlled trial of cognitive behavioural therapy in COPD
Karen Heslop-Marshall, Christine Baker, Debbie Carrick-Sen, Julia Newton, Carlos Echevarria, Chris Stenton, Michelle Jambon, Joanne Gray, Kim Pearce, Graham Burns, Anthony De Soyza
ERJ Open Research Oct 2018, 4 (4) 00094-2018; DOI: 10.1183/23120541.00094-2018
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Materials and methods
    • Results
    • Discussion
    • Supplementary material
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original articles

  • Endobronchial autologous BM-MSCs in IPF patients
  • Effect of β-blockers on the risk of COPD exacerbations
  • Recurrence of symptoms after childhood LRTI
Show more Original articles

COPD

  • A bronchial gene signature specific for severe COPD
  • Undiagnosed major cardiac comorbidities in COPD
  • Association of weather with variability in PA in COPD
Show more COPD

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2023 by the European Respiratory Society